Medcolcanna Organics Inc. Announces Listing on the Canadian Securities Exchange and Delisting of Common Shares from The NEO
Bogota, Colombia--(Newsfile Corp. - December 23, 2021) - Medcolcanna Organics Inc. (NEO: MCCN) ("Medcolcanna", "MCCN" or the "Company"), a Canadian integrated medical cannabis company with operations in Colombia, is pleased to announce that it has received approval to have the common shares of the Company ("Common Shares") listed on the Canadian Securities Exchange (the "CSE"). Consequently, the Company has also submitted a request to the Neo Exchange Inc. (the "NEO") to voluntarily delist the Common Shares from the NEO. The Company will be listing its Common Shares on the Canadian Securities Exchange (the "CSE") commencing at the opening of trading on December 30, 2021. The Common Shares are expected to be delisted from the Neo Exchange Inc. ("NEO") at close of business on December 29, 2021 and will begin trading on the CSE under the symbol "MCCN" at the opening bell on December 30, 2021. No action is required by shareholders in connection with this change of listing. For further information regarding the Company, please visit www.medcolcanna.com.
Company Management is excited with the prospect of listing the Common Shares on the CSE and the opportunities it provides to its investors, as the Company continues the ongoing development of its business operations, including pursuing operations in the United States as integral to its business and the value that it expects to provide to its shareholders. In addition, the Company expects that being listed on a junior stock exchange will help reduce the regulatory compliance costs for the Company and allow it to preserve capital while it continues to undertake its growth process and path towards financial self-sustainability.
Medcolcanna is a Canadian integrated medical cannabis company, whose fully licensed operations are based in Colombia. Led by a proven and successful management team, Medcolcanna has facilities in optimal growing locations which positions the Company to become a global leader in the medical cannabis market.
Medcolcanna employs state of the art organic agricultural technology and innovative pharmaceutical processes to produce high-quality products. The Company's scalable production model and network of pharmaceutical partnerships globally ensures that they remain at the forefront of the medical cannabis industry.
Additional information about Medcolcanna can be found on its web site at www.medcolcanna.com
Medcolcanna Investor Relations Contact:
Chris Reid, CFO
Carrera 49b # 93-62
Phone: +571 642-9113
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and the delay or failure to receive board, shareholder or regulatory approvals for any proposed transaction, including those discussed herein. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release.
Medcolcanna assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/108469